Please note, this OEL/ADE monograph also applies to loxapine succinate (CAS RN 27833-64-3). Loxapine is indicated to treat bipolar disorder and schizophrenia. Loxapine is a dibenzoxazepine compound, a subclass of tricyclic antipsychotic agents, chemically distinct from the phenothiazines, butyrophenones, thioxanthenes. Loxapine is dopamine antagonist and a serotonin 5-HT2 blocker. The exact mode of action has not been established; however, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species associated with calming effects and suppression of aggressive behavior.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Loxapine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.